​

Iovance Biotherapeutics (IOVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IOVA Stock Forecast

Iovance Biotherapeutics (IOVA) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $11.50, with a high of $17.00 and a low of $6.00. This represents a 275.82% increase from the last price of $3.06.

- $4 $8 $12 $16 $20 High: $17 Avg: $11.5 Low: $6 Last Closed Price: $3.06

IOVA Stock Rating

Iovance Biotherapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

IOVA Price Target Upside V Benchmarks

TypeNameUpside
StockIovance Biotherapeutics275.82%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-28
Avg Price Target-$6.75$11.19
Last Closing Price$3.06$3.06$3.06
Upside/Downside-120.59%265.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25481--13
Mar, 25482--14
Feb, 25482--14
Jan, 25492--15
Dec, 24492--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025Piper Sandler$6.00$4.2441.51%96.08%
Jan 31, 2025Joseph CatanzaroPiper Sandler$7.50$5.8528.21%145.10%
Oct 24, 2024David DaiUBS$17.00$9.8273.12%455.56%
Aug 09, 2024Benjamin BurnettStifel Nicolaus$11.50$3.97189.67%275.82%
Aug 09, 2024Colleen KusyRobert W. Baird$12.00$3.97202.27%292.16%
Jul 29, 2024Joseph CatanzaroPiper Sandler$10.00$9.258.11%226.80%
Jun 20, 2024Reni BenjaminJMP Securities$11.50$4.00187.50%275.82%
May 31, 2024Benjamin BurnettStifel Nicolaus$14.00$4.44215.32%357.52%
Mar 14, 2024Joseph CatanzaroPiper Sandler$19.00$14.2133.71%520.92%
Dec 08, 2022Madhu KumarGoldman Sachs$6.00$7.17-16.32%96.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 31, 2025Piper SandlerNeutralNeutralhold
Oct 24, 2024UBSBuyinitialise
Aug 14, 2024Cowen & Co.BuyBuyhold
Aug 12, 2024Piper SandlerMarket OutperformMarket Outperformhold
Jul 29, 2024Piper SandlerOverweightNeutraldowngrade
Jul 01, 2024H.C. WainwrightBuyBuyhold
Jun 20, 2024JMP SecuritiesOutperformOutperformhold
May 24, 2024Piper SandlerOverweightOverweighthold
Mar 14, 2024Piper SandlerOverweightOverweighthold
Feb 20, 2024Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.86$-1.89$-1.28----
Avg Forecast$-1.85$-1.87$-1.26$-0.85$-0.26$0.61$1.21
High Forecast$-1.75$-1.82$-0.87$-0.47$0.33$1.45$1.26
Low Forecast$-1.92$-1.89$-1.36$-1.18$-0.82$0.09$1.18
Surprise %0.54%1.07%1.59%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$1.19M$164.07M----
Avg Forecast$34.49M$4.42M$162.50M$459.05M$762.76M$1.03B$1.32B
High Forecast$41.39M$10.74M$167.95M$471.71M$770.50M$1.05B$1.36B
Low Forecast$27.59M$1.79M$160.30M$450.68M$755.03M$1.02B$1.30B
Surprise %--73.11%0.96%----

Net Income Forecast

$-450M $-290M $-130M $30M $190M $350M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-257.23M$-444.04M$-372.18M----
Avg Forecast$-264.23M$-444.04M$-262.78M$-249.15M$-68.71M$156.66M$285.10M
High Forecast$-211.39M$-428.17M$-204.92M$-110.50M$77.38M$339.95M$296.90M
Low Forecast$-317.08M$-444.55M$-320.65M$-277.41M$-193.68M$20.92M$278.21M
Surprise %-2.65%-41.63%----

IOVA Forecast FAQ

Is Iovance Biotherapeutics stock a buy?

Iovance Biotherapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Iovance Biotherapeutics is a favorable investment for most analysts.

What is Iovance Biotherapeutics's price target?

Iovance Biotherapeutics's price target, set by 18 Wall Street analysts, averages $11.5 over the next 12 months. The price target range spans from $6 at the low end to $17 at the high end, suggesting a potential 275.82% change from the previous closing price of $3.06.

How does Iovance Biotherapeutics stock forecast compare to its benchmarks?

Iovance Biotherapeutics's stock forecast shows a 275.82% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Iovance Biotherapeutics over the past three months?

  • April 2025: 30.77% Strong Buy, 61.54% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Iovance Biotherapeutics’s EPS forecast?

Iovance Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.85, marking a -33.59% decrease from the reported $-1.28 in 2024. Estimates for the following years are $-0.26 in 2026, $0.61 in 2027, and $1.21 in 2028.

What is Iovance Biotherapeutics’s revenue forecast?

Iovance Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $459.05M, reflecting a 179.79% increase from the reported $164.07M in 2024. The forecast for 2026 is $762.76M, followed by $1.03B for 2027, and $1.32B for 2028.

What is Iovance Biotherapeutics’s net income forecast?

Iovance Biotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-249M, representing a -33.06% decrease from the reported $-372M in 2024. Projections indicate $-68.714M in 2026, $156.66M in 2027, and $285.1M in 2028.